doi: 10.1161/01.HYP.0000014323.99765.16
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;39:929.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors
From the University of Connecticut School of Medicine (W.B.W.), Farmington; Pharmacia Clinical Research (J.K., K.M.V., J.B.L.), Skokie, Ill; Baylor College of Medicine (A.T.), Houston, Tex; and the Universal Clinical Research Center, Inc, and Johns Hopkins School of Medicine (A.W.), Baltimore, Md.
Correspondence to William B. White, MD, Professor and Chief, Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3940. E-mail wwhite{at}nso1.uchc.edu
Nonselective nonsteroidal anti-inflammatory agents have been shown to attenuate the antihypertensive efficacy of ACE inhibitors with average increases in systolic blood pressure (BP) of 5 to 10 mm Hg. Less is known about the specific cyclooxygenase-2 (COX-2) inhibitors now widely used for the treatment of arthritis. The objective of this study was to determine the effects of celecoxib compared with placebo on 24-hour BP levels in ACE inhibitor-treated patients with hypertension. This was a randomized, double-blind, placebo-controlled, parallel-group clinical trial involving 178 men and women (mean age, 53 years) with essential hypertension who were treated and controlled with lisinopril monotherapy (10 to 40 mg daily). Baseline BP values were obtained using 24-hour ambulatory recordings. Patients received either celecoxib, 200 mg twice daily (twice the recommended dose for osteoarthritis) (n=91), or placebo (n=87) for 4 weeks, and changes in the 24-hour BP, body weight, and clinical laboratory parameters were assessed. Mean changes from baseline in the 24-hour systolic and diastolic BP were 2.6/1.5±0.9/0.6 mm Hg on celecoxib versus 1.0/0.3±1/0.6 mm Hg on placebo (P=0.34 for systolic BP; P=0.45 for diastolic BP). The proportion of patients whose 24-hour BP increased by at least 5, 10, 15, or 20 mm Hg were also similar on celecoxib and placebo. No changes in body weight, serum creatinine, or potassium occurred in either group. Thus, these data demonstrate that high doses of celecoxib have no significant effect on the antihypertensive effect of the ACE inhibitor lisinopril. The placebo-subtracted changes observed in 24-hour BP (1.6/1.2 mm Hg) are less than what has been reported for nonselective nonsteroidal anti-inflammatory agents in ACE inhibitor-treated patients.
Key Words: angiotensin-converting enzyme inhibitors • antihypertensive agents • clinical trials • hypertension, essential • cyclooxygenase
This article has been cited by other articles:
 |
|
 |
|
  J. Chen, M. Zhao, W. He, G. L. Milne, J. R. H. Howard, J. Morrow, R. L. Hebert, R. M. Breyer, J. Chen, and C.-M. Hao Increased dietary NaCl induces renal medullary PGE2 production and natriuresis via the EP2 receptor Am J Physiol Renal Physiol, September 1, 2008; 295(3): F818 - F825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas Hypertension in rheumatoid arthritis Rheumatology, September 1, 2008; 47(9): 1286 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation, June 24, 2008; 117(25): e510 - e526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Calhoun, D. Jones, S. Textor, D. C. Goff, T. P. Murphy, R. D. Toto, A. White, W. C. Cushman, W. White, D. Sica, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension, June 1, 2008; 51(6): 1403 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ferrario Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word? Therapeutic Advances in Cardiovascular Disease, April 1, 2008; 2(2): 75 - 78. [PDF]
|
|
|
|
|
|
A. Aneja and M. E. Farkouh Review: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 53 - 66. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Salinas, U. C. Rangasetty, B. F. Uretsky, and Y. Birnbaum The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 98 - 111. [Abstract] [PDF]
|
|
|
|
|
|
W. B. White Cardiovascular Effects of the Cyclooxygenase Inhibitors Hypertension, March 1, 2007; 49(3): 408 - 418. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Solomon, M. A. Pfeffer, J. J.V. McMurray, R. Fowler, P. Finn, B. Levin, C. Eagle, E. Hawk, M. Lechuga, A. G. Zauber, et al. Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas Circulation, September 5, 2006; 114(10): 1028 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hermann and F. Ruschitzka Novel anti-inflammatory drugs in hypertension Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864. [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Harris and M. D. Breyer Update on Cyclooxygenase-2 Inhibitors Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-J. Aw, S. J. Haas, D. Liew, and H. Krum Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure Arch Intern Med, March 14, 2005; 165(5): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hermann, S. Shaw, E. Kiss, G. Camici, N. Buhler, R. Chenevard, T. F. Luscher, H. J. Grone, and F. Ruschitzka Selective COX-2 Inhibitors and Renal Injury in Salt-Sensitive Hypertension Hypertension, February 1, 2005; 45(2): 193 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sowers, W. B. White, B. Pitt, A. Whelton, L. S. Simon, N. Winer, A. Kivitz, H. van Ingen, T. Brabant, J. G. Fort, et al. The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus Arch Intern Med, January 24, 2005; 165(2): 161 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. White Hypertension Associated With Therapies to Treat Arthritis and Pain Hypertension, August 1, 2004; 44(2): 123 - 124. [Full Text] [PDF]
|
|
|
|
|
|
H.-F. Cheng and R. C. Harris Cyclooxygenases, the Kidney, and Hypertension Hypertension, March 1, 2004; 43(3): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Izhar, T. Alausa, A. Folker, E. Hung, and G. L. Bakris Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics Hypertension, March 1, 2004; 43(3): 573 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo Jr, D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright Jr, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension, December 1, 2003; 42(6): 1206 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L Johnson, T. M Hisel, and B. B. Phillips Effect of Cyclooxygenase-2 Inhibitors on Blood Pressure Ann. Pharmacother., March 1, 2003; 37(3): 442 - 446. [Abstract] [Full Text] [PDF]
|
|